培尼培南/倍它米隆治疗中-重度院内呼吸系统感染的初步研究

目的 观察培尼培南／倍它米隆(克倍宁)对下呼吸道感染的有效性及安全性，并通过体外药敏试验比较三种常用碳青酶烯类的抗菌活性特点。方法 11例急性中．重度的细菌性下呼吸道感染病例，予克倍宁1．5g／d，分3次给药，疗程为1～2周；同时对呼吸病房分离到的91株革兰阴性茵进行体外药敏的比较。结果 克倍宁的临床痊愈率为27．3％．有效率为81％．细菌清除率为9％．在治疗过程中未见不良反应发生；体外药敏检测提示克倍宁的抗茵活性与泰能和美平接近。结论 克倍宁在临床上对中．重度下呼吸道感染有良好效果，且不良反应较少。

The primary research of panipenam on middle to sever hospital acquired respiratory infection

Objective To observe the efficacy and safety of panipenam(CARBENIN) on respiratory infection and to compare with imipenam,meropenam in vitro drug sensitivity.Methods Eleven cases of middle to sever hospital acquired respiratory infection were received panipenam injection 1.5g three times per day for 7 to 14 days.In the meanwhile we tested the drug sensitivity of 91 strains which were received in our respiratory disease ward.Results The clinic recovery rate of panipenam were 30%,the effective rate were 80%,and the bacteria clear rate were 70%.There was no side effect appeared during the study.And panipenam's antimicrobial activity closed to the others.Conclusion Panipenam can be employed for treatment of hospital acquired respiratory infection with less side effective.